Our story
Ziab was founded to address a fundamental challenge in life science research: traditional antibody development is slow, expensive, and prone to failure.
The traditional approach requires animal immunization, lengthy screening processes, and costly production methods that haven't fundamentally changed in decades. With a 60% failure rate and development cycles of 6-8 months costing upwards of $50,000 per antibody, the status quo was ripe for disruption.
Our team of experts from leading research institutions and biotech companies came together with a bold vision: leverage cutting-edge AI and automation to transform antibody development from the ground up.
Today, Ziab is making that vision a reality - delivering antibodies in days instead of months, at a fraction of the traditional cost, while maintaining the highest standards of quality and consistency.
Our approach
At the core of our technology is a proprietary AI platform that designs antibody sequences directly from target proteins, eliminating the need for animal immunization and drastically reducing development time and cost.
Our focus on single domain antibodies (sdAbs) offers unique advantages:
- 10x smaller size enables applications like brain imaging and deep tumor penetration
- Enhanced stability and tissue penetration
- Faster development cycle and more consistent results
- On-demand production without large inventory requirements
Our end-to-end automated platform handles every step of the process:
- AI Generation: Our algorithms design optimized antibody sequences directly from target proteins
- High-Throughput Validation: Advanced mass spectrometry confirms binding and specificity
- Automated Production: Recombinant systems produce antibodies with consistent quality
- Rigorous Quality Control: Continuous monitoring ensures every product meets our standards
This integrated approach allows us to offer superior products at competitive prices while dramatically expanding the range of available antibodies.